Global Pharma Labs, Inc. is a pharmaceutical company. The San Leandro, California-based company is focused on developing solutions for disease processes in patients. Our technology, OA-SYSâ˘, is the first disease-modifying therapy for osteoarthritis, a disease which affects around 55 million people in the USA and approximately 750 million people globally. Global Pharma Labs Inc.âs first drug product, OA-SYSâ˘, will impact those that suffer with osteoarthritis. The immediate impact will be most apparent in developing countries where surgical joint replacement and joint injection therapy is not a practical treatment option for the vast majority of those suffering with the disease. OA-SYS⢠is the first disease modifying medication treatment for osteoarthritis. There are no competitors. Present medication treatment of osteoarthritis is limited to pain medicines which afford only temporary relief of pain, joint injections of steroids which affords only temporary relief of pain within the injected joint, and joint injections of Hyaluronic acid which also affords only temporary relief of pain within the injected joint. Global Pharma Labs Inc. has exclusive patent rights to the first disease modifying medication treatment for osteoarthritis. This patented treatment affords long term relief of joint pain, long term relief of joint stiffness, long term diminution of physical limitations, long term improvement in the ability to perform activities of daily living, reduction or elimination in the need for pain medications, and reduction or elimination in the need for invasive treatment such as joint replacement and joint injections. This treatment is disease modifying, noninvasive, nonnarcotic, and relatively inexpensive.
